Safety and Efficacy of LX4211 in Patients With Inadequately Controlled Type 1 Diabetes Mellitus
Status: | Completed |
---|---|
Conditions: | Diabetes |
Therapuetic Areas: | Endocrinology |
Healthy: | No |
Age Range: | 18 - 55 |
Updated: | 12/27/2017 |
Start Date: | February 2013 |
End Date: | January 2014 |
A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of LX4211 in Patients With Inadequately Controlled Type 1 Diabetes Mellitus
This Phase 2 study is intended to assess the pharmacodynamics (PD), pharmacokinetics (PK),
safety and efficacy of LX4211 following daily oral administration for 29 days in patients
with type 1 diabetes mellitus (T1DM).
safety and efficacy of LX4211 following daily oral administration for 29 days in patients
with type 1 diabetes mellitus (T1DM).
Inclusion Criteria:
- Adults ≥18 to ≤55 years of age
- Confirmed diagnosis of T1DM, diagnosed prior to age 40 years, and for at least 6
months prior to Screening
- Willing to refrain from using carbohydrate counting to adjust insulin during the study
- Willing and able to wear and operate a continuous glucose monitor
- Willing and able to self-assess blood-glucose
- Willing and able to provide written informed consent
Exclusion Criteria:
- History of type 2 diabetes mellitus or diabetes resulting from acromegaly, Cushing's
disease, chronic pancreatitis, or pancreatectomy
- Two or more severe episodes of hypoglycemia that required emergency treatment within 3
months prior to Screening
- Use of premixed insulin
- History of diabetic ketoacidosis within 1 year of screening
- Presence of active hepatic disease or clinically significant abnormal liver function
tests
- History of chronic pancreatitis
- Subjects with a history of heart attack, severe/unstable angina, or coronary
revascularization procedure
- History of clinically significant cardiac arrhythmias within 1 year prior to screening
- Subjects with congestive heart failure
- Subjects with uncontrolled Stage III hypertension
- History of human immunodeficiency virus (HIV) or hepatitis C
- History of illicit drug or alcohol abuse within 12 months prior to Screening
- Use of any investigational agent or device within 30 days prior to Screening or any
therapeutic protein or antibody within 90 days prior to Screening
- Use of medication or herbal supplements taken for weight loss within 2 weeks of
screening
- Chronic use of any antidiabetic therapy other than insulin within 2 months prior to
Screening
- Use of systemic or inhaled corticosteroids within 2 weeks prior to Screening
- Subjects who have undergone major surgery within 6 months prior to Screening
- Inability or difficulty swallowing whole tablets or capsules
- Women who are pregnant or breastfeeding
We found this trial at
7
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials